浙江龙盛今年以来股价涨3.88%，近5个交易日涨0.10%，近20日跌1.60%，近60日涨4.61%。 资料显示，浙江龙盛集团股份有限公司位于浙江省绍兴市上虞区道墟街道龙盛大道1号，成立日期1998 年3月23日，上市日期2003年8月1日，公司主营业务涉及染料、中间体、减水剂以及纯碱、合成氨等无 机化工产品。主营业务收入构成为：染料55.83%，中间体23.14%，助剂7.33%，无机产品5.08%，房产 业务3.48%，其它业务1.88%，汽配业务1.23%，颜色标准及可持续发展解决方案1.22%，其他(补 充)0.81%。 浙江龙盛所属申万行业为：基础化工-化学制品-纺织化学制品。所属概念板块包括：破净股、网约车概 念、透明工厂、染料涂料、参股新三板等。 截至6月30日，浙江龙盛股东户数11.87万，较上期减少4.67%；人均流通股27417股，较上期增加 4.90%。2025年1月-6月，浙江龙盛实现营业收入65.05亿元，同比减少6.47%；归母净利润9.28亿元，同 比增长2.84%。 9月17日，浙江龙盛盘中上涨2.05%，截至11:05，报10.43元/股，成交1.34亿元，换手率0.40% ...

9月16日，安诺其盘中上涨2.15%，截至10:04，报5.22元/股，成交4234.66万元，换手率0.88%，总市值 60.26亿元。 截至9月10日，安诺其股东户数5.26万，较上期减少2.69%；人均流通股17838股，较上期增加2.77%。 2025年1月-6月，安诺其实现营业收入5.12亿元，同比增长7.63%；归母净利润-1822.23万元，同比减少 263.80%。 分红方面，安诺其A股上市后累计派现3.45亿元。近三年，累计派现5771.87万元。 机构持仓方面，截止2025年6月30日，安诺其十大流通股东中，香港中央结算有限公司位居第十大流通 股东，持股216.83万股，相比上期减少399.16万股。 资金流向方面，主力资金净流出229.02万元，特大单买入0.00元，占比0.00%，卖出133.12万元，占比 3.14%；大单买入756.55万元，占比17.87%，卖出852.46万元，占比20.13%。 安诺其今年以来股价跌15.26%，近5个交易日涨0.77%，近20日跌3.15%，近60日跌7.94%。 今年以来安诺其已经1次登上龙虎榜，最近一次登上龙虎榜为3月21日，当日龙虎榜净 ...

Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

Group 1 - Xiyec股份 plans to repurchase company shares with a total amount between 100 million and 200 million yuan, at a price not exceeding 21.19 yuan per share [1] - Bee Assistant intends to acquire the remaining 30% stake in Guangdong Fengdang Technology Co., Ltd. for 206 million yuan, aiming to integrate industry resources [2] - *ST Gongzhi received a decision from the Shenzhen Stock Exchange regarding the termination of its stock listing, with the last trading date expected to be July 10, 2025 [2] Group 2 - *ST Jingfeng will cancel the delisting risk warning and continue to implement other risk warnings, with its stock name changing from "*ST Jingfeng" to "ST Jingfeng" [3] - Doli Technology plans to acquire 52% of Kunshan Fagerland Automotive Parts Co., Ltd. for 91.4653 million yuan to enhance its product structure [5] - Jinma Amusement's vice president plans to reduce holdings by up to 269,500 shares, accounting for 0.17% of the total share capital due to personal financial needs [6] Group 3 - Lingang股份 intends to absorb and merge its wholly-owned subsidiary Beipiao Steel Pipe, which will result in the cancellation of its independent legal status [7] - Demai Chemical plans to sell up to 4.5 million shares of Aoke股份 through various trading methods [9] - Shengxiang Bio plans to acquire 10% of Hunan Shengweis Rui Biotechnology Co., Ltd. for 5 million yuan to enhance its industry chain layout in sepsis diagnostics [10] Group 4 - Ha Sanlian's directors and executives plan to reduce their holdings by up to 252,200 shares, accounting for 0.08% of the total share capital [11] - Luoxin Pharmaceutical's shareholder plans to reduce holdings by up to 10.4421 million shares, representing 0.96% of the total share capital due to financial needs [13] - Hengbao股份's vice president plans to reduce holdings by up to 197,500 shares, accounting for 0.03% of the total share capital due to personal financial needs [15] Group 5 - Xianfeng Electronics' vice president plans to reduce holdings by up to 16,500 shares, accounting for 0.01% of the total share capital due to personal financial needs [16] - ST Jinyi will cancel other risk warnings, changing its stock name to "Jinyi Culture" and adjusting the daily price limit from 5% to 10% [16] - Vanke A completed the sale of all A-share treasury stock, raising 479 million yuan from the sale of 72.956 million shares [18] Group 6 - Taiji股份 is planning a change of control, leading to a temporary suspension of its stock trading for up to two days [20] - Lio股份's directors and executives plan to reduce their holdings by up to 6.7688 million shares, representing 0.1% of the total share capital [23] - Yuhuan CNC's vice president plans to reduce holdings by up to 46,100 shares, accounting for 0.0296% of the total share capital due to personal financial needs [24] Group 7 - Huamin股份 plans to invest up to 100 million yuan to acquire approximately 8% of Tiantai Robotics [24] - Enjie股份's shareholders plan to reduce their holdings by up to 1.19% of the total share capital due to personal financial needs [26] - Guoxin Securities plans to acquire 96.08% of Wanhua Securities through the issuance of A-shares, with the review scheduled for June 19, 2025 [27]

Group 1 - Leisai Intelligent adjusted the share repurchase price limit from 25.00 yuan/share to 52.00 yuan/share [1] - Fulin Precision's subsidiary Jiangxi Shenghua signed a supplementary agreement with CATL, involving a 500 million yuan advance payment for production capacity [1] - Shenzhou Cell plans to issue up to 25 million A-shares to its controlling shareholder to raise no more than 900 million yuan for working capital [2] Group 2 - BOE Technology received a commitment for an 1.8 billion yuan stock repurchase loan from China Construction Bank [2] - Chengjian Development plans to publicly transfer 9.24% equity in Beijing Science and Technology Park Construction Group at a minimum price of 282 million yuan [2][3] - *ST Lingda's chairman and president Wang Mingsheng resigned, with Jin Yongfeng elected as the new chairman [4] Group 3 - Jiangsu Boyun's shareholder plans to reduce holdings by up to 3% of the company's shares [6] - Yuhua Tian's shareholders plan to reduce holdings by up to 6% of the company's shares [8] - Anpei Long's shareholder plans to reduce holdings by up to 3% of the company's shares [10] Group 4 - Dayu Water-saving plans to participate in the auction for 70% equity of Huai'an Design Institute [15] - InSai Group intends to purchase 80% equity of Zhizhe Brand for 642 million yuan [16] - Jinj Chicken's shareholder plans to reduce holdings by up to 2.99% of the company's shares [18] Group 5 - Chao Hongji's shareholder plans to reduce holdings by up to 3% of the company's shares [19] - Chuangye Huikang's shareholder intends to transfer 40 million shares to repay stock pledge financing [20] - Zhuangzi Island's shareholder plans to reduce holdings by up to 1% of the company's shares [21] Group 6 - *ST Renle received a decision from the Shenzhen Stock Exchange to terminate its stock listing [22] - SMIC's wholly-owned subsidiary plans to sell 14.832% equity of a subsidiary to Hunan Guoke Microelectronics [24]

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]